von Willebrand factor (recombinant)
Trade name: Vonvendi
Recombinant proteinapprovedOrphan Drug FDA
Approved
Dec 8, 2015
Vonicog alfa, sold under the brand names Vonvendi and Veyvondi, is a medication used to control bleeding in adults with von Willebrand disease. It is a recombinant von Willebrand factor. — Wikipedia
Clinical trial activity
28 trials · 24 clinical orgs · 2 marketing orgs
Phase 1
4
Phase 2
15
Phase 3
14
Phase 4
6
Earliest trial started Oct 1, 1993 (NCT00004667)
Timeline
Indications
Approved for
Mechanism of action
- von Willebrand factorAGONIST
VWF agonist
- von Willebrand factorEXOGENOUS PROTEIN
von Willebrand factor exogenous protein
Approval history
- approvedDec 8, 2015
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVonicog alfa ↗
- NCATS5PKM8P0G5I ↗
- ChEMBLCHEMBL2107873 ↗
Also known as
- bax111
- bax 111
- human coagulation factor viii / human von willebrand factor
- voncento
- vonicog alfa
- vonicog alfa
- vonicog alfa
- vonicog alfa
- vonicog alfa
- vonvendi
- von willebrand factor
- von willebrand factor
- von willebrand factor
- von willebrand factor complex (human)
- von willebrand factor human
- von willebrand factor (human)
- von willebrand factor, human
- von willebrand factor (recombinant)
- von willebrand factor (recombinant)
- von willebrand factor (recombinant)
- von willebrand's factor
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07129343 | Phase 3 | Oct 12, 2025 | Takeda |
| NCT06205095 | Phase 3 | Jun 30, 2024 | Unity Health Toronto |
| NCT06118372 | Phase 1 | Jan 1, 2024 | University of Virginia |
| NCT05582993 | Phase 3 | Jan 9, 2023 | Takeda |
| NCT04953884 | Phase 3 | Jul 28, 2021 | Octapharma |
| NCT04555785 | Phase 4 | Nov 30, 2020 | University of Basel |
| NCT04344860 | Phase 3 | Sep 1, 2020 | University of Pittsburgh |
| NCT04052698 | Phase 3 | Jan 5, 2020 | Octapharma |
| NCT04046848 | Phase 1/Phase 2 (Phase 2) | Jul 3, 2019 | Octapharma |
| NCT03879135 | Phase 3 | Apr 1, 2019 | Shire |
| NCT03376516 | Phase 3 | Nov 22, 2017 | Octapharma |
| NCT02606045 | Phase 3 | Jul 1, 2017 | Carnegie Mellon University, Duke University, University of North Carolina at Chapel Hill, University of Pittsburgh |
| NCT03204539 | Phase 4 | Jun 1, 2017 | University of California, Davis |
| NCT02973087 | Phase 3 | Nov 1, 2016 | Baxalta |
| NCT02932618 | Phase 3 | Nov 1, 2016 | Baxalta |
| NCT02552576 | Phase 4 | Oct 1, 2015 | CSL Behring |
| NCT02283268 | Phase 3 | Apr 1, 2015 | Baxalta |
| NCT02479087 | Phase 4 | Jan 1, 2015 | Bankura Sammilani Medical College, Sintesi Research Srl, University of Milan |
| NCT02472665 | Phase 4 | Dec 1, 2013 | Grifols |
| NCT01410227 | Phase 3 | Nov 1, 2011 | Baxalta |
Showing 20 of 28 trials
Page 1 / 2
Organizations
Research & Development (24)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baxalta | For profit | 5 | 5 | 2 | 2008 |
| CSL Behring | For profit | 5 | 2 | 2 | 2001 |
| Octapharma | For profit | 5 | 5 | 2 | 2011 |
| Grifols | For profit | 3 | 1 | 2 | 2009 |
| Takeda | For profit | 3 | 3 | 2 | 2023 |
| Biotest Pharmaceuticals | For profit | 2 | 0 | 1 | 2009 |
| Charta Fondazione | Academic/Hospital | 2 | 0 | 1 | 2009 |
| City of Hope National Medical Center | Academic/Hospital | 2 | 2 | 1 | 2009 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 2 | 0 | 2 | 1993 |
| University of Pittsburgh | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Bankura Sammilani Medical College | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Blood Center of Wisconsin | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Carnegie Mellon University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Lund University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Mountain States Regional Hemophilia Center, Aurora, Columbia | Academic/Hospital | 1 | 0 | 1 | 2001 |
| National Center for Research Resources (NCRR) | Government | 1 | 1 | 1 | 1993 |
| Shire | For profit | 1 | 1 | 1 | 2019 |
| Sintesi Research Srl | For profit | 1 | 0 | 1 | 2015 |
| Unity Health Toronto | Academic/Hospital | 1 | 1 | 1 | 2024 |
24 organizations
Page 1 / 2